1. Patient-Centered Management in BRAF-Positive Metastatic Melanoma

4. Introduction

5. BRAF/MEK Inhibitor Combinations: Dabrafenib/Trametinib (COMBI-d)

6. COMBI-d Trial Updates Outcomes

7. COMBI-d Trial Updates Genomic Analysis

8. BRAF/MEK Inhibitor Combinations: Vemurafenib/Cobimetinib (coBRIM)

9. coBRIM Trial Update Outcomes

10. coBRIM Trial Update Predictors of Response

11. Single-Agent BRAF Inhibitor Advice From the Experts

12. First-Line Therapy Targeted Therapy or Immunotherapy?

13. Patient Selection for BRAF/MEK Therapy Expert Opinion

14. Patient Selection for BRAF/MEK Therapy

15. Additional Questions

16. AEs of BRAF/MEK Therapy

17. AEs of BRAF/MEK Therapy (cont)

18. AEs of BRAF/MEK Therapy (cont)

19. Which Combination to Choose?

20. Shared Decision-Making

21. Collaborating With Patients

22. Strategies for Better Communication

23. Working Across Specialties

24. Patient-Physician Communication

25. Concluding Remarks

26. Abbreviations